Interested in what the innovative but expensive therapies for Hepatitis C show us about the flawed economics of drug development, I explored the poor access U.S. prisoners have to effective cures, despite being a nexus of the disease.
On a more optimistic note, I wrote about the results that are possible when the drugs are priced at their marginal cost and the government makes them accessible to all who need them -- in Egypt.
